Please note: AABB reserves the right to make updates to this program.
Wednesday, July 11, 2018 - [Rescheduled from 8/15/18]
2:00 – 3:00 PM (ET) 7:00 – 8:00 PM (GMT)
Master Program Number: 18EL-351 (see program format numbers below under Registration)
Educational Track: Technical/Clinical
Topic: Transfusion Medicine
Intended Audience: Facilities that perform molecular testing, Hospitals, Hospital Blood Banks, Immunohematology Reference Labs (IRL’s), Laboratory Staff, Medical Directors, Physicians, Resident/Fellow, Students (MD, MT, SBB), Technologists
Teaching Level: Intermediate
Director/Moderator: Nancy M. Dunbar, MD, Medical Director, Blood Bank, Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH
Speaker: Meghan Delaney, DO, MPH, Chief, Pathology & Laboratory Medicine, Children’s National Health System, Washington, DC
After participating in this educational activity, participants should be able to:
- Explain current testing recommendations for management of pregnant women who have serological weak D.
- Discover how molecular testing can clarify serologic weak D testing results.
- Examine patient cases where molecular RhD testing guided pregnancy management.
Clarification of the underlying genotype of pregnant patients that have weak D phenotypes is important for pregnancy management including need for Rh Immune Globulin prophylaxis and red cell selection, if transfusion is indicated. Current guidelines describe recommendations for the application of molecular RhD testing in this setting. This one-hour case based program will review current recommendations for molecular RhD testing and illustrate how this testing guides the management of pregnant patients with serological weak D.
| || ||
|Single Viewer: Live||
|Single Viewer: On-Demand||
|Group Viewing: Live||
|Group Viewing: On-Demand||
|Group Viewing: Live & On-Demand||
Dr. Meghan Delaney is the Chief of Pathology & Laboratory Medicine at Children’s National Health System in Washington, DC. She focuses on pediatric transfusion medicine, the use of RBC genotyping to support patient care, as well as transfusion improvement and sustainable technology development in developing nations. Dr. Delaney chairs or serves on multiple committees for AABB, ASFA, and CAP. She is an Associate Editor for the journal
Transfusion Medicine, and is on the editorial board of
Transfusion. She is an Associate Scientific Member of the BEST Collaborative.